NEW YORK 212-530-5000

FAX: 212-530-5219

LOS ANGELES

213-897-4000

PAX: 213-67,9-5063

PALO ALTO 650-739-7000

FAX: 650-730-7100

LONDON 44-207-448-3000

FAX: 44-207-448-3029

MILBANK, TWEED, HADLEY & MCLOY LLP

INTERNATIONAL SQUARE BUILDING

1850 K STREET, N. W., SUITE 1100

WASHINGTON, D.C. 20006

202-\$35-7500 FAX: 202-834-7585

EINAR STOLE, Ph.D. DIKECT DIAL NUMBER 7.02-835-7553

E-MAII, estole@milbank.com

RECEIVED CENTRAL FAX CENTER NOV 21 2008

TOKYO 813-3504-1040 FAX: 813-3595-2790

HONG KONG \$52-2971-4888 PAX: 852-2840-0702

SINGAPORE 65-428-2400 FAX: 65-428-2500

FRANKFURY 49-69-7593-7170 PAX: 49-69-7593-8303

FACSIMILE TRANSMISSION

DATE:

November 21, 2008

To:

Nume		
NAME	FAX No.	PHONE NO.
US Patent and Trademark Office	(571) 273-8300	120/10/10:
	(5.1) 275 11300	

FROM:

Einar Stole

PHONE:

(2.02) 835-7553

RE:

U.S. Patent Application Scrial No. 10/519,110

FILE NUMBER: 17357.0100IUS				l
NUMBER OF PAGES, INCLUDING COVER:	66	Originals Follow by Mail:	NO	

MESSAGE:

Please see attached First Supplemental Information Disclosure Statement dated November 21, 2008. Kindly acknowledge receipt of this communication.

Finar Stole

RECEIVED

Hodoub - B.	40.0	PTC/SB/21 (03- PTC/SB/21 (03- Potent and Trademark (Micre U.S. DEPARTMENT OF COMMEN Epological information unless & disclose a veil CMB control wash	RECEIVED
Under the Pastawork Reduction Act of 19	96. no serions are required to respond to a cell Application Number		NOV 2 1 2008
TRANSMITTAL	Filing Date	10/519,110	1.00 21 200
FORM	First Named Inventor	July 2, 2008	7
. Orchy	An Unil	Elchober/igeray	
		16:17	┪
(to be used for all correspondence after initial		Not Yet Assigned	
Total Number of Pages In This Submission	Attorney Docker Number	17357.01001US	7
	ENCLOSURES (Check all the	that apply)	7
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TO	-
Fee Altachad	Ucensing-related Papers	Appeal Communication to Board of Appeals and Interterences	
Amendment/Reply	Petition Petition to Convert to a	Appeal Communication to TC (Appeal Notice, Brief, Repty Krief)	
After Finel	Provisional Application	Proprietary Information	
Attidavits/nectaration(s)	Change of Correspondence Add		
Extension of Time Request	Terminal Dischimer	Other Endosure(s) (please identify below):	
FXPress Abandonment Request	Request for Refund		
Information Prisclosure Statement	CO, Number of CD(s)		
	Landscape Table on CD	·	
Certified Copy of Priority Document(s)	Remarks		
Reply to Missing Parts/	1. Copy of 1 Ciled Reference		
Incomplete Application Reply to Missing Paris			
under 37 CFR 1.52 vi 1.53	•		
SIGNAT	TIPE OF APPLIA		
	TURE OF APPLICANT, ATTORN	EY, OR AGENT	
Milbank, Tyresch Hadley & I Signature	McClay LLD		
Printed pame	12/1		*
Emar Stole			
Dale November 21, 2009	Rey.	No. 47,272	
CE	RTIE(CATE OF YEAR)		
I hereby certify that this emphased and the	RTIFICATE OF TRANSMISSION		
the date shown below:	tope addressed to: Cumulissioner for Part	deposited with the United States Postal Service with Shis, P.O., Box 1450, Alexandria, VA 22313-1450 on	
19-	STAT	>	
Typed or printed name Einar Stole		Date November 21, 20na	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 33 U.S.C. 127 and 37 CFR 1.11 and 1.14. This collection is cellmated to 2 hours to complete, including gathering, proparing, and sutmitted in 2 hours to complete, including amount of the USPTO. Time will vary depending upon the intributed case. Any comments on the Impulsion of the USPTO of the will vary depending upon the intributed case. Any comments on the Impulsion of the USPTO. Proceedings of the burden, about to the Chief Information Officer, U.S. Patient and ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1460, Alexandria, VA 22313-1450. DO NOT GEND FEES ON COMPLETED FORMS TO THIS

If you need assistence in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. PATENT SERIAL NO. 10/519,110 Attorney Docket No. 17357.01001US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
NOV 2 1 2008

In re Application of:)
Rene Etcheberrigary et al.) Group Art Unit: 1617
Patent Application No. 10/519,110) Examiner: Not Yet Assigned
Filed: July 2, 2003)
For: PKC Activation As A Means For Enchancing sAPPa Secretion and Improving Cognition Using Bryostatin Type Compounds))))

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT Commissioner of Patents U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in C.F.R. § 1.56, applicants are submitting herewith copies of references listed on the attached Form PTO/SB/08A for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Applicants have attached a copy of European Publication No. EP 0115472, published August 8, 1984 (Beneze et al.), which was cited in the European application corresponding to this application. In accordance with 37 C.F.R. § 1.98(a)(3)(i), Beneze et al. disclose certain pyrrolidinone derivatives, a process and new intermediates for the preparation of these compounds, and their use for the production of pharmaceutical preparations or as pharmacologically active compounds. Beneze et al. disclose that these compounds can be used for the treatment of insufficiency of cerebral ability, including Alzheimer's disease.

Applicants cannot locate a translation of or an English-language application corresponding to Beneze et al. Accordingly, a translation of Beneze et al. has not been submitted because

DC1#8154476

PAGE 3/66 * RCVD AT 11/21/2008 2:20:17 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/32 * DNIS:2738300 * CSID:202 835 7586 * DURATION (mm-ss):15-22

U.S. PATENT SERIAL NO. 10/519,110 Attorney Docket No. 17357.01001US

"a written English-language translation ... is [not] within the possession, custody, or control of, [and] is [not] readily available to any individual designated in § 1.56(c)." See § 1.98(a)(3)(ii).

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO/SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

Applicants' submission of the Information Disclosure Statement (IDS) shall not be construed as an admission that the cited references are prior art to the present invention, or that the cited references qualify as printed publications. The submission of this IDS also shall not be construed as a representation that a prior art search has been performed.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted before the mailing of a first Official Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in any event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No., 13-3250 under referenced No. 17357.01001US.

Respectfully submitted,

MILBANK, TWEED, HADLEY & McCLOY LLP

Date: November 21, 2008

By:

Einar Stole Registration No. 47,272

Customer No. 38647
MILBANK, TWEED, HADLEY & McCLOY LLP
1850 K Street, N.W., Suite 1100
Washington, DC 20006
Tel. No. (202) 835-7500
Fax No. (202) 835-7586

	Application Number	10519110	RECEIVED
INFORMATION DISCLOSURE	Filing Date	2003-07-02	CENTRAL FAX CENTER
STATEMENT BY APPLICANT	First Named Inventor	Etchobernigaray	NOV 2 1 2008
(Not for submission under 37 CFR 1.99)	Art Unit	1617	
•	Examiner Name	Not Yet Assigned	
	Attorney Dacket Numb	per 17387.01001US	
		——————————————————————————————————————	

		CERTIFICAT	ION STATEMENT	
Please see 37	CFR 1,97 and 1,98 to make ti	he appropriate sel	ection(s):	
That each from a for informatio	item of information containe elgn patent office in a count n disclosure statement, See'3	ed in the Informativerpart foreign app 7 CFR 1.97(e)(1).	on disclosure statement w dication not more than th	vas first cited in any communication ree months prior to the filing of the
OR			•	
				e cited in a communication from a the person signing the certification disclosure statement was known to filing of the Information disclosure
	ed certification statement h in 37 CFR 1.17 (p) has beer	n submitted herewi	fth.	
	e applicant or representative ture.	SIGNA is required in accord	ATURE Irdance with CFR 1.33, 10.	.18, Piease see CFR 1.4(d) for the
ignature ame/Print	6-5	TOU	Date (YYYY-MM-DD)	2008-11-21
SINCIP IIII	Einar Stole		Registration Number	47.272
plication form to quire to comple stent and Trade	ton is estimated to take 1 hours of the USPTO. Time will vary of this form and/or suggestion.	r to complete, include the complete, include the complete	iding gathering, preparing e individual case. Any cor burden, should be eent to	red to obtain or retain a benefit by the med by 35 U.S.C. 122 and 37 CFR and submitting the completed mments on the amount of time you the Chief Information Officer, U.S. A 22313-1450. DO NOT SEND ents, P.O. Box 1450, Alexandria.